Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000069.xml
Semin Liver Dis 2000; 20(4): 511-522
DOI: 10.1055/s-2000-13159
DOI: 10.1055/s-2000-13159
Prospects for Xenotransplantation of the Liver
Akiyoshi Kanazawa1 , Jeffrey L. Platt2- Departments of Surgery and Immunology,
- 1 Mayo Clinic, Rochester, Minnesota and Departments of Surgery and Pediatrics
- 2, Mayo Clinic, Rochester, Minnesota. Reprint request: Dr. Jeffrey L. Platt, Transplantation Biology, 2-66 Medical Sciences Building, Mayo Clinic, 200 First Street Southwest, Rochester, Minnesota 55905. E-mail: platt.jeffrey@mayo.edu
Further Information
Publication History
Publication Date:
31 December 2000 (online)
ABSTRACT
A severe shortage of human livers for allotransplantation has sparked interest in the potential use of animals in lieu of humans as a source of livers, that is xenotransplantation. Xenotransplantation might also provide a means by which recurrence of hepatitis might be averted. Among the types of xenografts that might be undertaken are extracorporeal ``xenoperfusion'' or perfusion of devices containing xenogeneic hepatocytes, auxiliary liver transplants, bridge liver transplants, and hepatocyte transplants. The hurdles to xenotransplantation of the liver include the immune response of the recipient against the graft, incompatibility of the graft with complex physiologic and biochemical systems of the recipient, and the possibility of transferring infectious agent from the graft to the recipient. Recent progress in characterizing and overcoming these hurdles has encouraged some optimism regarding the ultimate application of xenotransplantation for the treatment of human disease.
KEYWORD
xenotransplantation - liver - immunology
REFERENCES
- 1 Harper A M, Rosendale J D, McBride M A, Cherikh W S, Ellison M D. The UNOS OPTN waiting list and donor registry. Clin Transpl . 1998; 3
- 2 Starzl T E, Fung J, Tzakis A. Baboon-to-human liver transplantation. Lancet . 1993; 341 65-71
- 3 Blau H M, Springer M L. Muscle-mediated gene therapy. N Engl J Med . 1995; 333 1554-1556
- 4 Platt J L. New directions for organ transplantation. Nature . 1998; 392(suppl) 11-17
- 5 Reemtsma K, McCracken B H, Schlegel J U. Renal heterotransplantation in man. Ann Surg . 1964; 160 384-410
- 6 Allan J S. Xenotransplantation at a crossroads: prevention versus progress. Nat Med . 1996; 2 18-21
- 7 White D, Wallwork J. Xenografting: probability, possibility, or pipe dream?. Lancet . 1993; 342 879-880
- 8 Platt J L, Logan J S. Use of transgenic animals in xenotransplantation. Transplantation Reviews . 1996; 10 69-77
- 9 Kelly D A, Mayer D. Liver transplantation. In: Kelly DA, ed. Diseases of the Liver and Biliary System in Children Oxford: Blackwell Science 1999: 293-312
- 10 Rosen H, Shackeleton C, Martin P. Indications for and timing of liver transplantation. In: Martin P, Friedman L, eds. The Medical Clinics of North America: Management of Chronic Liver Disease Philidelphia: WB Saunders 1996: 1069-1102
- 11 Starzl T E, Tzakis A, Fung J J. Prospects of clinical xenotransplantation. Transpl Proc . 1994; 26 1082-1088
- 12 Taniguchi S, Cooper D KC. Clinical xenotransplantation-a brief review of the world experience. In: Cooper DKC, Kemp E, Platt JL, White DJG, eds. Xenotransplantation 2nd ed. Berlin: Springer-Verlag 1997: 776-784
- 13 Starzl T E, Putnam C W, Porter K A. Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transpl Proc . 1974; 6 129-139
- 14 Giles G R, Boehmig H J, Amemiya H, Halgrimson C G, Starzl T E. Clinical heterotransplantation of the liver. Transpl Proc . 1970; 2 506-512
- 15 Starzl T E. Liver transplantation. Gastroenterology . 1997; 112 288-291
- 16 Fung J, Rao A, Phil D, Starzl T. Clinical trials and projected future of liver xenotransplantation. World J Surg . 1997; 21 956-961
- 17 Makowka L, Cramer D V, Hoffman A. The use of a pig liver xenograft for temporary support of a patient with fulminant hepatic failure. Transplantation . 1995; 59 1654-1659
- 18 Rela M, Muiesan P, Vilca-Melendez H. Auxiliary partial orthotopic liver transplantation for Crigler-Najjar syndrome type I. Ann Surg . 1999; 229 565-569
- 19 Wang X, Andersson R. Hepatocyte transplantation: a potential treatment for acute liver failure. Scand J Gastroenterol . 1995; 30 193-200
- 20 Kobayashi N, Fujiwara T, Westerman K A. Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes. Science . 2000; 287 1258-1262
- 21 Fox I, Chowdhury J, Kaufman S. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med . 1998; 338 1422-1426
- 22 Lake J. Hepatocyte Transplantation. N Engl J Med . 1998; 338 1463-1465
- 23 Gunsalus J R, Brady D A, Coulter S M, Gray B M, Edge A. Reduction of serum cholesterol in watanabe rabbits by xenogeneic hepatocellular transplantation. Nat Med . 1997; 3 48-53
- 24 Hoopes C W, Platt J L. Hepatocyte transplantation: history, immunology, and potential for clinical application. Biotech Lab International . 1998; 3 11-14
- 25 Edge A SB, Gosse M E, Dinsmore J. Xenogeneic cell therapy: current progress and future developments in porcine cell transplantation. Cell Transplantation . 1998; 7 525-539
- 26 Wakizaka Y, Miki T, Rao A S. Correction of congenital hyperbilirubinemia in homozygous Gunn rats by xenotransplantation of hamster livers. Xenotransplantation . 1997; 4 262-266
- 27 Abouna G M, Kirkley J R, Hull C J, Ashcroft T, Kerr D NS. Treatment of hepatic coma by extracorporeal pig-liver perfusion. Lancet . 1969; 1 64-68
- 28 Chari R S, Collins B H, Magee J C. Treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation. N Engl J Med . 1994; 331 234-237
- 29 Abouna G M. Extracorporeal xenogeneic liver perfusion for the treatment of hepatic failure. In: Cooper DKC, Kemp E, Platt JL, White DJG, eds. Xenotransplantation: the Transplantation of Organs and Tissues between Species 2nd ed. Berlin: Springer; 1997
- 30 Watanabe F D, Mullon C J, Hewitt W R. Clinical experience with a bioartifical liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg . 1997; 225 484-491
- 31 Chen S C, Mullon C, Kahaku E. Treatment of severe liver failure with a bioartificial liver. Ann NY Acad Sci . 1997; 831 350-360
- 32 Bismuth H, Figueiro J, Samuel D. What should we expect from a bioartificial liver in fulminant hepatic failure?. Artificial Organs . 1998; 22 26-31
- 33 Platt J L. Hyperacute Xenograft Rejection. Medical Intelligence Unit. Austin, TX: RG Landes; 1995
- 34 Platt J L, Fischel R J, Matas A J. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation . 1991; 52 214-220
- 35 Galili U, Clark M R, Shohet S B, Buehler J, Macher B A. Evolutionary relationship between the natural anti-Gal antibody and the Galα1-3Gal epitope in primates. Proc Natl Acad Sci U S A . 1987; 84 1369-1373
- 36 Geller R L, Rubinstein P, Platt J L. Variation in expression of porcine xenogeneic antigens. Transplantation . 1994; 58 272-277
- 37 Calne R Y, Davis D R, Pena J R. Hepatic allografts and xenografts in primates. Lancet . 1970; 1 103-106
- 38 Collins B H, Chari R S, Magee J C. Mechanisms of injury in porcine livers perfused with blood of humans with fulminant hepatic failure. Transplantation . 1994; 58 1162-1171
- 39 Knechtle S J, Kolbeck P C, Tsuchimoto S. Hepatic transplantation into sensitized recipients: demonstration of hyperacute rejection. Transplantation . 1987; 43 8-12
- 40 Merion R M, Colletti L M. Hyperacute rejection in porcine liver transplantation: I. Clinical characteristics, histopathology, and disappearance of donor-specific lymphocytotoxic antibody from serum. Transplantation . 1990; 49 861-868
- 41 Lin S S, Kooyman D L, Daniels L J. The role of natural anti-Galα1-3Gal antibodies in hyperacute rejection of pig-to-baboon cardiac xenotransplants. Transpl Immunol . 1997; 5 212-218
- 42 Leventhal J R, Dalmasso A P, Cromwell J W. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation . 1993; 55 857-866
- 43 Pruitt S K, Kirk A D, Bollinger R R. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation . 1994; 57 363-370
- 44 Magee J C, Collins B H, Harland R C. Immunoglobulin prevents complement mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest . 1995; 96 2404-2412
- 45 Platt J L, Vercellotti G M, Dalmasso A P. Transplantation of discordant xenografts: a review of progress. Immunology Today . 1990; 11 450-456
- 46 Logan J S, Martin M J. Transgenic swine as a recombinant production system for human hemoglobin. Methods in Enzymology . 1994; 231 435-445
- 47 McCurry K R, Kooyman D L, Alvarado C G. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat Med . 1995; 1 423-427
- 48 Byrne G W, McCurry K R, Martin M J. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation . 1997; 63 149-155
- 49 Cozzi E, Yannoutsos N, Langford G A, Pino-Chavez G, Wallwork J, White D JG. Effect of transgenic expression of human decay-accelerating factor on the inhibition of hyperacute rejection of pig organs. In: Cooper DKC, Kemp E, Platt JL, White DJG, eds. Xenotransplantation: the Transplantation of Organs and Tissues between Species 2nd ed. Berlin: Springer 1997: 665-682
- 50 Dalmasso A P, Vercellotti G M, Platt J L, Bach F H. Inhibition of complement-mediated endothelial cell cytotoxicity by decay accelerating factor: potential for prevention of xenograft hyperacute rejection. Transplantation . 1991; 52 530-533
- 51 Sandrin M S, Fodor W L, Mouhtouris E. Enzymatic remodelling of the carbohydrate surface of a xenogeneic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nat Med . 1995; 1 1261-1267
- 52 Thall A D, Mal¿ P, Lowe J B. Oocyte Gala1,3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. J Biol Chem . 1995; 270 21437-21440
- 53 Leventhal J R, Matas A J, Sun L H. The immunopathology of cardiac xenograft rejection in the guinea pig-to-rat model. Transplantation . 1993; 56 1-8
- 54 Porter K A. Renal Transplantation. In: Heptinstall RH, ed. Pathology of the Kidney, Vol III. 4th ed. Boston, MA: Little, Brown 1992: 1799-1933
- 55 Gugenheim J, Samuel D, Reynes M, Bismuth H. Liver transplantation across ABO blood group barriers. Lancet . 1990; 336 519-523
- 56 Platt J L, Lin S S, McGregor C GA. Acute vascular rejection. Xenotransplantation . 1998; 5 169-175
- 57 Bach F H, Winkler H, Ferran C, Hancock W W, Robson S C. Delayed xenograft rejection. Immunology Today . 1996; 17 379-384
- 58 Lawson J H, Platt J L. Molecular barriers to xenotransplantation. Transplantation . 1996; 62 303-310
- 59 Lin S S, Weidner B C, Byrne G W. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants. J Clin Invest . 1998; 101 1745-1756
- 60 Chopek M W, Simmons R L, Platt J L. ABO-incompatible renal transplantation: initial immunopathologic evaluation. Transpl Proc . 1987; 19 4553-4557
- 61 Bannett A D, McAlack R F, Morris M, Chopek M, Platt J L. ABO incompatible renal transplantation: a qualitative analysis of native endothelial tissue ABO antigens after transplant. Transpl Proc. 1989; 21 783-785
- 62 Parker W, Saadi S, Lin S S, Holzknecht Z E, Bustos M, Platt J L. Transplantation of discordant xenografts: a challenge revisited. Immunology Today . 1996; 17 373-378
- 63 Bach F H, Hancock W W, Ferran C. Protective genes expressed in endothelial cells: a regulatory response to injury. Immunology Today . 1997; 18 483-486
- 64 Sachs D H, Sablinski T. Tolerance across discordant xenogeneic barriers. Xenotransplantation . 1995; 2 234-239
- 65 Ildstad S T, Vacchio M S, Markus P M, Hronakes M L, Wren S M, Hodes R J. Cross-species transplantation tolerance: rat bone marrow-derived cells can contribute to the ligand for negative selection of mouse T cell receptor Vb in chimeras tolerant to xenogeneic antigens (mouse + rat → mouse). J Exper Med . 1992; 175 147-155
- 66 Zhao Y, Swenson K, Sergio J J, Arn J S, Sachs D H, Sykes M. Skin graft tolerance across a discordant xenogeneic barrier. Nat Med . 1996; 2 1211-1216
- 67 Inverardi L, Samaja M, Motterlini R, Mangili F, Bender J R, Pardi R. Early recognition of a discordant xenogeneic organ by human circulating lymphocytes. J Immunol . 1992; 149 1416-1423
- 68 Starzl T E, Demetris A J, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, chimerism, and graft acceptance. Lancet . 1992; 339 1579-1582
- 69 Holzknecht Z E, Coombes S, Blocher B A. Evidence of immunocomplex formation in pulmonary xenografts. Transpl Proc . 2000; 32 1411
- 70 Lawson J H, Platt J L. Xenotransplantation: prospects for clinical application. In: Owen W, Pereira B, M S, eds. Dialysis and Transplantation: A Companion to Brenner and Rector's The Kidney Philadelphia: WB Saunders 2000: 653-660
- 71 Daggett C W, Yeatman M, Lodge A J. Total respiratory support from swine lungs in primate recipients. J Thorac Cardiovasc Surg . 1998; 115 19-27
- 72 Lawson J H, Daniels L, Platt J L. The evaluation of thrombomodulin activity in porcine to human xenotransplantation. Transplant Proc . 1997; 29 884-885
- 73 Edwards J. Complement activation by xenogeneic red blood cells. Transplantation . 1981; 31 226-227
- 74 Desille M, Corcos L, L'Helgoualc'h A. Detoxifying activity in pig livers and hepatocytes intended for xenotherapy. Transplantation . 1999; 68 1437-1443
- 75 Patience C, Takeuchi Y, Weiss R A. Infection of human cells by an endogenous retrovirus of pigs. Nat Med . 1997; 3 282-286
- 76 Patience C, Patton G S, Takeuchi Y. No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys. Lancet . 1998; 352 699-701
- 77 Paradis K, Langford G, Long Z. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. Science . 1999; 285 1236-1241
- 78 Platt J. ``Xenoassistance devices'' for the treatment of hepatic failure: challenges and controversies. Transpl Proc (in press).